Impact of desloratadine on symptoms and quality of life in subjects with chronic idiopathic urticaria: A multicenter, practice-based study

Archives of Drug Information

Volumn 1, Issue 2, 2008, Pages 63-69

  Kim, Harold ^a,b   Lynde, Charles ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b WESTERN UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Chronic Idiopathic Urticaria; Desloratadine; Quality of Life

Indexed keywords

CETIRIZINE; DESLORATADINE; DIPHENHYDRAMINE;

ABSENCE OF SIDE EFFECTS; AERIUS QUALITY OF LIFE QUESTIONNAIRE; ARTICLE; CHRONIC IDIOPATHIC URTICARIA; CLINICAL TRIAL; CREAM; DAILY LIFE ACTIVITY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPEN STUDY; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; QUESTIONNAIRE; RISK REDUCTION; SCORING SYSTEM; SLEEP DISTURBANCE SCORE; SLEEP PATTERN; SYMPTOMATOLOGY; TREATMENT RESPONSE; URTICARIA;

EID: 75149112963     PISSN: None     EISSN: 17535174     Source Type: Journal    
DOI: 10.1111/j.1753-5174.2008.00010.x     Document Type: Article

References (24)

1. Lachapelle JM, Decroix J, Henrijean A, Roquet-Gravy PP, De Swerdt A, Boonen H, etal. Desloratadine 5 mg once daily improves the quality of life of patients with chronic idiopathic urticaria. J Eur Acad Dermatol Venereol 2006;20:288-92.
2. Champion RH. Urticaria: Then and now. Br J Dermatol 1988;119:427-36.
3. Strachan DD. Urticaria, chronic. Available at: http://www.emedicine.com/ derm/topic443.htm (accessed February 26, 2008).
4. Sabroe RA, Greaves MW. The pathogenesis of chronic urticaria. Arch Dermatol 1997;133:1003-8.
5. 2LEN/EDF guideline: Definition, classification and diagnosis of urticaria. Allergy 2006;61:316-20.
6. 2LEN/EDF guideline: Management of urticaria. Allergy 2006;61:321-31.
7. Gruber BL, Baeza ML, Marchese MJ, Agnello V, Kaplan AP. Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol 1988;90:213-7.
8. Grattan CEH, Francis DM, Hide M, Greaves MW. Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin Exp Allergy 1991;21:695-704.
9. Hide M, Francis DM, Grattan C, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993;328:1599-604.
10. Zweiman B, Valenzano M, Atkins PC, Tanus T, Getsy JA. Characteristics of histamine-releasing activity in the sera of patients with chronic idiopathic urticaria. J Allergy Clin Immunol 1996;98:89-98.
11. Tong LJ, Balakrishnan G, Kochan JP, Kinét J-P, Kaplan AP. Assessment of autoimmunity in patients with chronic urticaria. J Allergy Clin Immunol 1997;99:461-5.
12. Sheikh J. Urticaria. Available at: http://www.emedicine.com/med/ topic3014.htm (accessed February 26, 2008).
13. Greaves M. Chronic urticaria. J Allergy Clin Immunol 2000;105:664-72.
14. O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997;136:197-201.
15. Grob J-J, Gaudy-Marqueste C. Urticaria and quality of life. Clin Rev Allergy Immunol 2006;30:47-51.
16. Baiardini I, Giardini A, Pasquali M, Dignetti P, Guerra L, Specchia C, et al. Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy. Allergy 2003;58:621-3.
17. Staubach P, Eckhardt-Henn A, Dechene M, Vonend A, Metz M, Magerl M, et al. Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol 2006;154:294-8.
18. Sabroe RA, Seed PT, Stat C, Francis DM, Barr RM, Kobza Black A, et al. Chronic idiopathic urticaria: Comparison of the clinical features of patients with and without anti-FcεRI or anti-IgE autoantibodies. J Am Acad Dermatol 1999;40:443-50.
19. Poon E, Seed PT, Greaves MW, Kobza-Black A. The extent and nature of disability in different urticarial conditions. Br J Dermatol 1999;140:667-71.
20. Lee EE, Maibach HI. Treatment of urticaria: An evidence-based evaluation of antihistamines. Am J Clin Dermatol 2001;2:27-32.
21. Ring J, Hein R, Gauger A, Bronsky E, Miller B, and the Desloratadine Study Group. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: A randomized, double-blind, placebo-controlled study. Int J Dermatol 2001;40:72-6.
22. Monroe E, Finn A, Patel P, Guerrero R, Ratner P, Bernstein D, and the Desloratadine Urticaria Study Group. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: A double-blind randomized, placebo-controlled trial. J Am Acad Dermatol 2003;48:535-41.
23. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - A simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-6.
24. Thompson AK, Finn AF, Schoenwetter WF. Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria. J Am Acad Dermatol 2000;43(pt. 1):24-30.